Drug Database · Clinicians

Ticagrelor

Brands (23) Brilinta, Reclovac 90, Agraplat…Show all

P2Y12 Platelet Inhibitor (P2Y12 Receptor Antagonists; Cytochrome P450 3A4 Inhibitors; P-Glycoprotein Inhibitors) US FDA class
Antithrombotic agent (platelet aggregation inhibitor excl. heparin); Platelet aggregation inhibitor excl. heparin; and others PH FDA category

Rx · Prescription drug28 PH products
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID f7b3f443-e83d-4bf2-0e96-023448fed9a8, version date May 7, 2026 (BRILINTA · AstraZeneca Pharmaceuticals LP). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior…
  • to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events.
  • to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA).
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE BRILINTA is a P2Y 12 platelet inhibitor indicated

  • to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1)
  • to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM). (1.2)
  • to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). (1.3) 1.1 Acute Coronary Syndrome or a History of Myocardial Infarction BRILINTA is indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS [see Clinical Studies (14.1)]. 1.2 Coronary Artery Disease but No Prior Stroke or Myocardial Infarction BRILINTA is indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events [see Clinical Studies (14.2)]. While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM). 1.3 Acute Ischemic Stroke or Transient Ischemic Attack (TIA) BRILINTA is indicated to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA) [see Clinical Studies (14.3)].

Contraindications

4 CONTRAINDICATIONS

  • History of intracranial hemorrhage. (4.1)
  • Active pathological bleeding. (4.2)
  • Hypersensitivity to ticagrelor or any component of the product. (4.3) 4.1 History of Intracranial Hemorrhage BRILINTA is contraindicated in patients with a history of intracranial hemorrhage (ICH) because of a high risk of recurrent ICH in this population [see Clinical Studies (14.1), (14.2)]. 4.2 Active Bleeding BRILINTA is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)]. 4.3 Hypersensitivity BRILINTA is contraindicated in patients with hypersensitivity (e.g., angioedema) to ticagrelor or any component of the product.
US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • • ACS or History of MI • Initiate treatment with 180 mg oral loading dose of BRILINTA. Then administer 90 mg twice daily during the first year. After one year, administer 60 mg twice daily. (2.2)
  • • Patients with CAD and No Prior Stroke or MI • Administer 60 mg BRILINTA twice daily. (2.3)
  • • Acute Ischemic Stroke • Initiate treatment with a 180 mg loading dose of BRILINTA then continue with 90 mg twice daily for up to 30 days. (2.4)
  • Use BRILINTA with a daily maintenance dose of aspirin of 75-100 mg. (2) However, in patients who have undergone PCI, consider single antiplatelet therapy with BRILINTA based on the evolving risk for thrombotic versus bleeding events. (2.2)
2.1 General Instructions

2.1 General Instructions Advise patients who miss a dose of BRILINTA to take their next dose at its scheduled time. For patients who are unable to swallow tablets whole, BRILINTA tablets can be crushed, mixed with water, and drunk. The mixture can also be administered via a nasogastric tube (CH8 or greater) [see Clinical Pharmacology (12.3)].

Do not administer BRILINTA with another oral P2Y 12 platelet inhibitor. Avoid aspirin at doses higher than recommended [see Clinical Studies (14.1)].

2.2 Acute Coronary Syndrome or a History of Myocardial Infarction

2.2 Acute Coronary Syndrome or a History of Myocardial Infarction Initiate treatment with a 180 mg loading dose of BRILINTA. Administer the first 90 mg maintenance dose of BRILINTA, 6 to 12 hours after the loading dose. Administer 90 mg of BRILINTA twice daily during the first year after an ACS event. After one year, administer 60 mg of BRILINTA twice daily.

Initiate BRILINTA with a daily maintenance dose of aspirin of 75 mg to 100 mg. However, in patients who have undergone percutaneous coronary intervention (PCI), consider single antiplatelet therapy with BRILINTA based on the evolving risk for thrombotic versus bleeding events [see Warnings and Precautions (5.1) and Clinical Studies (14)].

2.3 Coronary Artery

2.3 Coronary Artery Disease but No Prior Stroke or Myocardial Infarction Administer 60 mg of BRILINTA twice daily. Generally, use BRILINTA with a daily maintenance dose of aspirin of 75 mg to 100 mg [see Clinical Studies (14)].

2.4 Acute Ischemic Stroke or Transient

2.4 Acute Ischemic Stroke or Transient Ischemic Attack (TIA) Initiate treatment with a 180 mg loading dose of BRILINTA and then continue with 90 mg twice daily for up to 30 days. Administer the first maintenance dose 6 to 12 hours after the loading dose. Use BRILINTA with a loading dose of aspirin (300 mg to 325 mg) and a daily maintenance dose of aspirin of 75 mg to 100 mg [see Clinical Studies (14)].

Dosing: Altered kidney function

From the US FDA label · Renal impairment (use in specific populations)

8.7 Renal Impairment No dosage adjustment is needed in patients with renal impairment [see Clinical Pharmacology (12.3)]. Patients with End-Stage Renal Disease on dialysis Clinical efficacy and safety studies with BRILINTA did not enroll patients with end-stage renal disease (ESRD) on dialysis. In patients with ESRD maintained on intermittent hemodialysis, no clinically significant difference in concentrations of ticagrelor and its metabolite and platelet inhibition are expected compared to those observed in patients with normal renal function [see Clinical Pharmacology (12.3)].

It is not known whether these concentrations will lead to similar efficacy and safety in patients with ESRD on dialysis as were seen in PLATO, PEGASUS, THEMIS and THALES.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Hepatic impairment

8.6 Hepatic Impairment Ticagrelor is metabolized by the liver and impaired hepatic function can increase risks for bleeding and other adverse events. Avoid use of BRILINTA in patients with severe hepatic impairment. There is limited experience with BRILINTA in patients with moderate hepatic impairment; consider the risks and benefits of treatment, noting the probable increase in exposure to ticagrelor. No dosage adjustment is needed in patients with mild hepatic impairment [see Warnings and Precautions (5.5) and Clinical Pharmacology (12.3)].

US FDA label

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use The safety and effectiveness of BRILINTA have not been established in pediatric patients. Effectiveness was not demonstrated in an adequate and well-controlled study conducted in 101 BRILINTA-treated pediatric patients, aged 2 to <18 for reducing the rate of vaso-occlusive crises in sickle cell disease.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use About half of the patients in PLATO, PEGASUS, THEMIS, and THALES were ≥65 years of age and at least 15% were ≥75 years of age. No overall differences in safety or effectiveness were observed between elderly and younger patients.

Dosage forms

Philippines

  • Film-coated tablet: 60 mg, 90 mg
  • Tablet: 90 mg

Registered products in the Philippines

28 products registered with the Food and Drug Administration (FDA) Philippines list Ticagrelor as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products28
Philippine FDA-registered products for Ticagrelor
Package insert
AgraplatTicagrelor
90 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 30's)
Rx
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines, Inc.Importer: Ajanta Pharma Philippines Inc..
DR-XY47658
Jan 10, 2027
BricorTicagrelor
90 mg Film-Coated TabletAlu/Clear PVC-PVDC Blister Pack x 10's (Box of 60's)
Rx
Lloyd Laboratories, Inc.Bulacan
Trader: Innogen Pharmaceuticals, Inc.
DRP-15165
Sep 23, 2031
BrilintaTicagrelor
60 mg Film-Coated TabletAlu/Clear PVC/PVDC Blister Pack x 10's (Box of 60's)
Rx
Astrazeneca ABSweden
AstraZeneca Pharmaceuticals (Phils.), Inc.
DR-XY45981
Aug 15, 2027
BrilintaTicagrelor
90 mg Film-Coated TabletAlu/Clear PVC/PVDC Blister Pack x 10's (Box of 60's)
Rx
AstraZeneca ABSweden
Importer: AstraZeneca Pharmaceuticals (Phils.), Inc.
DR-XY40759
Mar 21, 2027
BrilintaTicagrelor
90 mg Film-Coated TabletAlu/Clear PVC/PVDC Blister Pack x 10's (Box of 60's)
Rx
AstraZeneca Pharmaceutical Company Ltd.China
AstraZeneca Pharmaceuticals (Phils.), Inc.
DR-XY49659
Feb 27, 2031
BriMaedTicagrelor
90 mg Film-Coated TabletAlu / Alu Blister Pack x 10's (Box of 30's)
Rx
Medisure Laboratories Pakistan (Pvt.) LimitedPakistan
Maed Pharma CorporationImporter: Accesspoint International Trading, Inc.
DRP-13260-01
Jan 18, 2028
ClevergeTicagrelor
90 mg Film-Coated TabletAlu/Clear PVC-PVC Blister Pack x 10's (Box of 60's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: One Pharma Marketing Inc.
DR-XY48422
Oct 13, 2027
Cordgrelor 90Ticagrelor
90mg Film Coated TabletAlu/PVC-PVDC Blister Pack x 10's (Box of 60's)
Rx
Intas Pharmaceuticals LimitedIndia
Accord Healthcare Limited
DRP-16638
May 23, 2030
DethromTicagrelor
90 mg Film-Coated TabletAlu- Alu Blister Pack x 10's (Box of 30’s)
Rx
Flourish PharmaIndia
NAB Trading Corp.Importer: Biophil Medical Equipment and Supplies Trading
DRP-16177-01
Dec 10, 2029
Gretor 60Ticagrelor
60 mg Film-Coated TabletAlu/Alu blister pack x 10's (box of 30's)
Rx
Torrent Pharmaceuticals Ltd.India
Torrent Pharma Philippines, Inc.
DR-XY48168
Jul 5, 2027
Gretor 90Ticagrelor
90 mg Film-Coated TabletAlu/Alu blister pack x 10's (box of 30's)
Rx
Torrent Pharmaceuticals Ltd.India
Torrent Pharma Philippines, Inc.
DR-XY48167
Jul 5, 2027
Medglor 60Ticagrelor
60 mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 14's (Box of 14's)
Rx
Exemed PharmaceuticalsIndia
SRS Life Sciences Inc.
DR-XY49409
Jun 2, 2030
Medglor 90Ticagrelor
90 mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 14's (Box of 14 tablets)
Rx
Exemed PharmaceuticalsIndia
SRS Life Sciences Inc.
DR-XY 49093
May 24, 2029
Plintor 90Ticagrelor
90 mg Film-Coated TabletPVC/PE/PVDC aluminum blister pack x 10's (Box of 60's)
Rx
Annora Pharma Private LimitedIndia
Camber Pharmaceuticals, Inc.
DRP-18516
Jul 27, 2031
Prevatac 90Ticagrelor
90 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 60's)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambica International Corporation.Importer: Ambica International Corporation
DRP-14596
Oct 20, 2028
Reclovac 90Ticagrelor
90 mg TabletPVC/PE/PVDC-Alu Blister Pack x 15's (Box of 15's)
Rx
Dr. Reddy's Laboratories LimitedIndia
Importer: Dr. Reddy's Laboratories Philippines Inc.
DRP-17007
Sep 5, 2030
Reclovac 90Ticagrelor
90 mg TabletHDPE Bottle x 60's (Box of 60's)
Rx
Dr. Reddy's Laboratories LimitedIndia
Dr. Reddy's Laboratories Philippines Inc.
DRP-17008
Sep 5, 2030
Tgson-90Ticagrelor
90 mg Film-Coated TabletAlu/PVC-PVDC Blister Pack x 14's (Box of 28's)
Rx
Unison Pharmaceuticals Pvt. Ltd.India
Macropharma Corporation
DRP-16408
Mar 4, 2030
TicaalorTicagrelor
90mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Medisure Laboratories Pakistan (Pvt.) Ltd.Pakistan
Stangen Pharmaceuticals Philippines Inc.
DRP-12058
Jun 6, 2027
TicafredTicagrelor
90 mg Film-Coated TabletAlu-Alu Blister Pack x 10 (Box of 30's)
Rx
Fredun Pharmaceuticals LimitedIndia
AMB HK Enterprises Inc.
DRP-15866
Sep 25, 2029
TicagresaphTicagrelor
90 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Sapphire Lifesciences Pvt. Ltd.India
Nelpa Lifesciences, Inc.Trader: Aaron Healthcare and Export Pvt. Ltd.
DRP-15485
Jul 16, 2029
TicardiaTicagrelor
90 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 60’s)
Rx
Stallion Laboratories Pvt. Ltd.India
Getz Pharma (Phils.), Inc.Importer: Ambica International Corporation
DRP-14596-01
Oct 20, 2028
TiclotTicagrelor
90 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Globela Pharma Private LimitedIndia
AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc.
DRP-14576
Oct 18, 2028
Tigemac 90Ticagrelor
90 mg Film-Coated TabletAlu/Clear PVC/PVDC Blister Pack of 3 x 10's (Box of 30), 6 x 10's (Box of 60), 8 x 7's (Box of 56)
Rx
Macleods Pharmaceuticals LimitedIndia
Macleods Pharmaceuticals Philippines, Inc.
DR-XY49051
Apr 17, 2029
TiglorTicagrelor
90 mg Film Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Micro Labs LimitedIndia
Brown & Burk Philippines Inc.
DRP-10974
Dec 27, 2031
TigralorTicagrelor
90 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Medisure Laboratories Pakistan (Pvt.) Ltd.Pakistan
Accesspoint International Trading, Inc.
DRP-13260
Jan 18, 2028
(no brand name)Ticagrelor
90 mg Film-Coated TabletAlu/Clear PVC-PVdC Blister Pack x 10's (Box of 60's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Dr. Zen's Research, Inc.
DR-XY48576
Jan 23, 2028
(no brand name)Ticagrelor
90 mg Film-Coated TabletAlu/Clear PVC-PVC Blister Pack x 10's (Box of 60's)
Rx
Lloyd Laboratories, Inc.Philippines
—
DRP-12844
Oct 13, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS BRILINTA (ticagrelor) 90 mg is supplied as a round, biconvex, yellow, film-coated tablet marked with a “90” above “T” on one side. BRILINTA (ticagrelor) 60 mg is supplied as a round, biconvex, pink, film-coated tablet marked with “60” above “T” on one side. • 60 mg and 90 mg tablets (3)

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label
  • • Dyspnea was reported more frequently with BRILINTA than with control agents in clinical trials. Dyspnea from BRILINTA is self-limiting. (5.3)
  • • Severe Hepatic Impairment: Likely increase in exposure to ticagrelor. (5.6)
  • • Laboratory Test Interference: False negative platelet functional test results have been reported for Heparin Induced Thrombocytopenia (HIT). BRILINTA is not expected to impact PF4 antibody testing for HIT. (5.8)
5.1 Risk of Bleeding

5.1 Risk of Bleeding Drugs that inhibit platelet function including BRILINTA increase the risk of bleeding [see Warnings and Precautions (5.2) and Adverse Reactions (6.1)]. Patients treated for acute ischemic stroke or TIA Patients at NIHSS >5 and patients receiving thrombolysis were excluded from THALES and use of BRILINTA in such patients is not recommended.

5.2 Discontinuation

5.2 Discontinuation of BRILINTA in Patients Treated for Coronary Artery Disease Discontinuation of BRILINTA will increase the risk of myocardial infarction, stroke, and death in patients being treated for coronary artery disease. If BRILINTA must be temporarily discontinued (e.g., to treat bleeding or for significant surgery), restart it as soon as possible.

When possible, interrupt therapy with BRILINTA for five days prior to surgery that has a major risk of bleeding. Resume BRILINTA as soon as hemostasis is achieved.

5.3 Dyspnea

5.3 Dyspnea In clinical trials, about 14% (PLATO and PEGASUS) to 21% (THEMIS) of patients treated with BRILINTA developed dyspnea. Dyspnea was usually mild to moderate in intensity and often resolved during continued treatment but led to study drug discontinuation in 0.9% (PLATO), 1.0% (THALES), 4.3% (PEGASUS), and 6.9% (THEMIS) of patients.

In a substudy of PLATO, 199 subjects underwent pulmonary function testing irrespective of whether they reported dyspnea. There was no indication of an adverse effect on pulmonary function assessed after one month or after at least 6 months of chronic treatment. If a patient develops new, prolonged, or worsened dyspnea that is determined to be related to BRILINTA, no specific treatment is required; continue BRILINTA without interruption if possible.

In the case of intolerable dyspnea requiring discontinuation of BRILINTA, consider prescribing another antiplatelet agent.

5.4 Bradyarrhythmias

5.4 Bradyarrhythmias BRILINTA can cause ventricular pauses [see Adverse Reactions (6.1)]. Bradyarrhythmias including AV block have been reported in the postmarketing setting. Patients with a history of sick sinus syndrome, 2 nd or 3 rd degree AV block or bradycardia-related syncope not protected by a pacemaker were excluded from clinical studies and may be at increased risk of developing bradyarrhythmias with ticagrelor.

5.5 Severe Hepatic Impairment

5.5 Severe Hepatic Impairment Avoid use of BRILINTA in patients with severe hepatic impairment. Severe hepatic impairment is likely to increase serum concentration of ticagrelor. There are no studies of BRILINTA patients with severe hepatic impairment [see Clinical Pharmacology (12.3)].

5.6 Central Sleep Apnea

5.6 Central Sleep Apnea Central sleep apnea (CSA) including Cheyne-Stokes respiration (CSR) has been reported in the post-marketing setting in patients taking ticagrelor, including recurrence or worsening of CSA/CSR following rechallenge. If central sleep apnea is suspected, consider further clinical assessment.

5.7 Laboratory Test Interferences

5.7 Laboratory Test Interferences False negative functional tests for Heparin Induced Thrombocytopenia (HIT) BRILINTA has been reported to cause false negative results in platelet functional tests (including the heparin-induced platelet aggregation (HIPA) assay) for patients with Heparin Induced Thrombocytopenia (HIT). This is related to inhibition of the P2Y 12 -receptor on the healthy donor platelets in the test by ticagrelor in the affected patient’s serum/plasma.

Information on concomitant treatment with BRILINTA is required for interpretation of HIT functional tests. Based on the mechanism of BRILINTA interference, BRILINTA is not expected to impact PF4 antibody testing for HIT.

Drug interactions

Drug interactions (US label) US FDA label
  • • Avoid use with strong CYP3A inhibitors or CYP3A inducers. (7.1, 7.2)
  • • Opioids: Decreased exposure to ticagrelor. Consider use of parenteral anti-platelet agent. (7.3)
  • • Patients receiving more than 40 mg per day of simvastatin or lovastatin may be at increased risk of statin-related adverse effects. (7.4)
  • • Rosuvastatin plasma concentrations may increase. Monitor for statin-related adverse effects. (7.4)
  • • Monitor digoxin levels with initiation of or any change in BRILINTA. (7.5)
7.1 Strong CYP3A Inhibitors

7.1 Strong CYP3A Inhibitors Strong CYP3A inhibitors substantially increase ticagrelor exposure and so increase the risk of dyspnea, bleeding, and other adverse events. Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [see Clinical Pharmacology (12.3)].

7.2 Strong CYP3A Inducers

7.2 Strong CYP3A Inducers Strong CYP3A inducers substantially reduce ticagrelor exposure and so decrease the efficacy of ticagrelor. Avoid use with strong inducers of CYP3A (e.g., rifampin, phenytoin, carbamazepine and phenobarbital) [see Clinical Pharmacology (12.3)].

7.3 Opioids

7.3 Opioids As with other oral P2Y 12 inhibitors, co-administration of opioid agonists delay and reduce the absorption of ticagrelor and its active metabolite presumably because of slowed gastric emptying [see Clinical Pharmacology (12.3)]. Consider the use of a parenteral anti-platelet agent in acute coronary syndrome patients requiring co-administration of morphine or other opioid agonists.

7.4 Simvastatin, Lovastatin, Rosuvastatin

7.4 Simvastatin, Lovastatin, Rosuvastatin BRILINTA increases serum concentrations of simvastatin and lovastatin because these drugs are metabolized by CYP3A4. Avoid simvastatin and lovastatin doses greater than 40 mg [see Clinical Pharmacology (12.3)]. Brilinta increases serum concentration of rosuvastatin because rosuvastatin is a BCRP substrate [see Clinical Pharmacology (12.3)].

7.5 Digoxin

7.5 Digoxin BRILINTA inhibits the P-glycoprotein transporter; monitor digoxin levels with initiation of or change in BRILINTA therapy [see Clinical Pharmacology (12.3)].

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Metabolism CYP3A4 is the major enzyme responsible for ticagrelor metabolism and the formation of its major active metabolite.

Ticagrelor and its major active metabolite are weak P-glycoprotein substrates and inhibitors.

Ticagrelor is a BCRP inhibitor.

Figure 7 - Impact of intrinsic factors on the pharmacokinetics of ticagrelor Effects of Other Drugs on BRILINTA CYP3A4 is the major enzyme responsible for ticagrelor metabolism and the formation of its major active metabolite.

Strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, and clarithromycin) substantially increase ticagrelor exposure.

Moderate CYP3A inhibitors have lesser effects (e.g., diltiazem).

CYP3A inducers (e.g., rifampin) substantially reduce ticagrelor blood levels.

P-gp inhibitors (e.g., cyclosporine) increase ticagrelor exposure.

Adverse reactions

Adverse reactions (US label) US FDA label
  • The following adverse reactions are also discussed elsewhere in the labeling: • Bleeding [see Warnings and Precautions (5.1)] • Dyspnea [see Warnings and Precautions (5.3)] Most common adverse reactions (>5%) are bleeding and dyspnea. (5.1, 5.3, 6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. BRILINTA has been evaluated for safety in more than 58,000 patients.

Bleeding in PLATO (Reduction in risk of thrombotic events in ACS) Figure 1 is a plot of time to the first non-CABG major bleeding event. Figure 1 - Kaplan-Meier estimate of time to first non-CABG PLATO-defined major bleeding event (PLATO) Frequency of bleeding in PLATO is summarized in Tables 1 and 2. About half of the non-CABG major bleeding events were in the first 30 days.

Table 1 - Non-CABG related bleeds (PLATO) BRILINTA 90 mg BID N=9235 Clopidogrel N=9186 n (%) patients with event n (%) patients with event PLATO Major + Minor 713 (7.7) 567 (6.2) Major 362 (3.9) 306 (3.3) Fatal/Life-threatening 171 (1.9) 151 (1.6) Fatal 15 (0.2) 16 (0.2) Intracranial hemorrhage (Fatal/Life-threatening) 26 (0.3) 15 (0.2) PLATO Minor bleed: requires medical intervention to stop or treat bleeding. PLATO Major bleed: any one of the following: fatal; intracranial; intrapericardial with cardiac tamponade; hypovolemic shock or severe hypotension requiring intervention; significantly disabling (e.g., intraocular with permanent vision loss); associated with a decrease in Hb of at least 3 g/dL (or a fall in hematocrit (Hct) of at least 9%); transfusion of 2 or more units.

PLATO Major bleed, fatal/life-threatening: any major bleed as described above and associated with a decrease in Hb of more than 5 g/dL (or a fall in hematocrit (Hct) of at least 15%); transfusion of 4 or more units. Fatal: A bleeding event that directly led to death within 7 days. No baseline demographic factor altered the relative risk of bleeding with BRILINTA compared to clopidogrel.

In PLATO, 1584 patients underwent CABG surgery. The percentages of those patients who bled are shown in Figure 2 and Table 2. Figure 2 - ‘Major fatal/life-threatening’ CABG-related bleeding by days from last dose of study drug to CABG procedure (PLATO) X-axis is days from last dose of study drug prior to CABG. The PLATO protocol recommended a procedure for withholding study drug prior to CABG or other major surgery without unblinding.

If surgery was elective or non-urgent, study drug was interrupted temporarily, as follows: If local practice was to allow antiplatelet effects to dissipate before surgery, capsules (blinded clopidogrel) were withheld 5 days before surgery and tablets (blinded ticagrelor) were withheld for a minimum of 24 hours and a maximum of 72 hours before surgery. If local practice was to perform surgery without waiting for dissipation of antiplatelet effects capsules and tablets were withheld 24 hours prior to surgery and use of aprotinin or other hemostatic agents was allowed.

If local practice was to use IPA monitoring to determine when surgery could be performed both the capsules and tablets were withheld at the same time and the usual monitoring procedures followed. T Ticagrelor; C Clopidogrel. Table 2 - CABG-related bleeding (PLATO) BRILINTA 90 mg BID N=770 Clopidogrel N=814 n (%) patients with event n (%) patients with event PLATO Total Major 626 (81.3) 666 (81.8) Fatal/Life-threatening 337 (43.8) 350 (43.0) Fatal 6 (0.8) 7 (0.9) PLATO Major bleed: any one of the following: fatal; intracranial; intrapericardial with cardiac tamponade; hypovolemic shock or severe hypotension requiring intervention; significantly disabling (e.g., intraocular with permanent vision loss); associated with a decrease in Hb of at least 3 g/dL (or a fall in hematocrit (Hct) of at least 9%); transfusion of 2 or more units.

PLATO Major bleed, fatal/life-threatening: any major bleed as described above and associated with a decrease in Hb of more than 5 g/dL (or a fall in hematocrit (Hct) of at least 15%); transfusion of 4 or more units. When antiplatelet therapy was stopped 5 days before CABG, major bleeding occurred in 75% of BRILINTA treated patients and 79% on clopidogrel.

Other Adverse Reactions in PLATO Adverse reactions that occurred at a rate of 4% or more in PLATO are shown in Table 3. Table 3 - Percentage of patients reporting non-hemorrhagic adverse reactions at least 4% or more in either group and more frequently on BRILINTA (PLATO) BRILINTA 90 mg BID N=9235 Clopidogrel N=9186 Dyspnea 13.8 7.8 Dizziness 4.5 3.9 Nausea 4.3 3.8 Bleeding in PEGASUS (Secondary Prevention in Patients with a History of Myocardial Infarction) Overall outcome of bleeding events in the PEGASUS study are shown in Table 4.

Table 4 - Bleeding events (PEGASUS) BRILINTA 60 mg BID N=6958 Placebo N=6996 Events / 1000 patient years Events / 1000 patient years TIMI Major 8 3 Fatal 1 1 Intracranial hemorrhage 2 1 TIMI Major or Minor 11 5 TIMI Major: Fatal bleeding, OR any intracranial bleeding, OR clinically overt signs of hemorrhage associated with a drop in hemoglobin (Hgb) of ≥5 g/dL, or a fall in hematocrit (Hct) of ≥15%. Fatal: A bleeding event that directly led to death within 7 days.

TIMI Minor: Clinically apparent with 3-5 g/dL decrease in hemoglobin. The bleeding profile of BRILINTA 60 mg compared to aspirin alone was consistent across multiple pre-defined subgroups (e.g., by age, gender, weight, race, geographic region, concurrent conditions, concomitant therapy, stent, and medical history) for TIMI Major and TIMI Major or Minor bleeding events.

Other Adverse Reactions in PEGASUS Adverse reactions that occurred in PEGASUS at rates of 3% or more are shown in Table 5. Table 5 - Non-hemorrhagic adverse reactions reported in >3.0% of patients in the ticagrelor 60 mg treatment group (PEGASUS) BRILINTA 60 mg BID N=6958 Placebo N=6996 Dyspnea 14.2% 5.5% Dizziness 4.5% 4.1% Diarrhea 3.3% 2.5% Bleeding in THEMIS (Prevention of major CV events in patients with CAD and Type 2 Diabetes Mellitus) The Kaplan-Meier curve of time to first TIMI Major bleeding event is presented in Figure 3.

Figure 3 – Time to first TIMI Major bleeding event (THEMIS) T = Ticagrelor; P = Placebo; N = Number of patients The bleeding events in THEMIS are shown below in Table 6. Table 6 – Bleeding events (THEMIS) BRILINTA N=9562 Placebo N=9531 Events / 1000 patient years Events / 1000 patient years TIMI Major 9 4 TIMI Major or Minor 12 5 TIMI Major or Minor or Requiring medical attention 46 18 Fatal bleeding 1 0 Intracranial hemorrhage 3 2 Bleeding in THALES (Reduction in risk of stroke in patients with acute ischemic stroke or TIA) The Kaplan-Meier curve of time course of GUSTO severe bleeding events is presented in Figure 4.

Figure 4 – Time course of GUSTO severe bleeding events KM%: Kaplan-Meier percentage evaluated at Day 30; T = Ticagrelor; P = placebo; N = Number of patients GUSTO Severe: Any one of the following: fatal bleeding, intracranial bleeding (excluding asymptomatic hemorrhagic transformations of ischemic brain infarctions and excluding microhemorrhages < 10 mm evident only on gradient-echo magnetic resonance imaging), bleeding that caused hemodynamic compromise requiring intervention (e.g., systolic blood pressure <90 mg Hg that required blood or fluid replacement, or vasopressor/inotropic support, or surgical intervention). Intracranial bleeding and fatal bleeding in THALES: In total, there were 21 intracranial hemorrhages (ICHs) for BRILINTA and 6 ICHs for placebo.

Fatal bleedings, almost all ICH, occurred in 11 for BRILINTA and in 2 for placebo. Bradycardia In a Holter substudy of about 3000 patients in PLATO, more patients had ventricular pauses with BRILINTA (6.0%) than with clopidogrel (3.5%) in the acute phase; rates were 2.2% and 1.6%, respectively, after 1 month. PLATO, PEGASUS, THEMIS and THALES excluded patients at increased risk of bradycardic events (e.g., patients who have sick sinus syndrome, 2 nd or 3 rd degree AV block, or bradycardic-related syncope and not protected with a pacemaker).

Lab abnormalities Serum Uric Acid: In PLATO, serum uric acid levels increased approximately 0.6 mg/dL from baseline on BRILINTA 90 mg and approximately 0.2 mg/dL on clopidogrel. The difference disappeared within 30 days of discontinuing treatment. Reports of gout did not differ between treatment groups in PLATO (0.6% in each group).

In PEGASUS, serum uric acid levels increased approximately 0.2 mg/dL from baseline on BRILINTA 60 mg and no elevation was observed on aspirin alone. Gout occurred more commonly in patients on BRILINTA than in patients on aspirin alone (1.5%, 1.1%). Mean serum uric acid concentrations decreased after treatment was stopped.

Serum Creatinine: In PLATO, a >50% increase in serum creatinine levels was observed in 7.4% of patients receiving BRILINTA 90 mg compared to 5.9% of patients receiving clopidogrel. The increases typically did not progress with ongoing treatment and often decreased with continued therapy. Evidence of reversibility upon discontinuation was observed even in those with the greatest on treatment increases.

Treatment groups in PLATO did not differ for renal-related serious adverse events such as acute renal failure, chronic renal failure, toxic nephropathy, or oliguria. In PEGASUS, serum creatinine concentration increased by >50% in approximately 4% of patients receiving BRILINTA 60 mg, similar to aspirin alone. The frequency of renal related adverse events was similar for ticagrelor and aspirin alone regardless of age and baseline renal function. figure_1 fiigure_2 figure_3 figure_4

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of BRILINTA. Because these reactions are reported voluntarily from a population of an unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Blood and lymphatic system disorders: Thrombotic Thrombocytopenic Purpura (TTP) has been rarely reported with the use of BRILINTA. TTP is a serious condition which can occur after a brief exposure (<2 weeks) and requires prompt treatment. Immune system disorders: Hypersensitivity reactions including angioedema [see Contraindications (4.3)].

Respiratory Disorders: Central sleep apnea, Cheyne-Stokes respiration Skin and subcutaneous tissue disorders: Rash

Adverse reaction frequency tables (US label) US FDA label
Table 1 - Non-CABG related bleeds (PLATO)
BRILINTA90 mg BID N=9235Clopidogrel N=9186
n (%) patientswith eventn (%) patientswith event
PLATO Major + Minor713 (7.7)567 (6.2)
Major362 (3.9)306 (3.3)
Fatal/Life-threatening171 (1.9)151 (1.6)
Fatal15 (0.2)16 (0.2)
Intracranial hemorrhage (Fatal/Life-threatening)26 (0.3)15 (0.2)
PLATO Minor bleed: requires medical intervention to stop or treat bleeding.PLATO Major bleed: any one of the following: fatal; intracranial; intrapericardial with cardiac tamponade; hypovolemic shock or severe hypotension requiring intervention; significantly disabling (e.g., intraocular with permanent vision loss); associated with a decrease in Hb of at least 3 g/dL (or a fall in hematocrit (Hct) of at least 9%); transfusion of 2 or more units.PLATO Major bleed, fatal/life-threatening: any major bleed as described above and associated with a decrease in Hb of more than 5 g/dL (or a fall in hematocrit (Hct) of at least 15%); transfusion of 4 or more units.Fatal: A bleeding event that directly led to death within 7 days.
Table 2 - CABG-related bleeding (PLATO)
BRILINTA90 mg BIDN=770ClopidogrelN=814
n (%) patientswith eventn (%) patientswith event
PLATO Total Major626 (81.3)666 (81.8)
Fatal/Life-threatening337 (43.8)350 (43.0)
Fatal6 (0.8)7 (0.9)
PLATO Major bleed: any one of the following: fatal; intracranial; intrapericardial with cardiac tamponade; hypovolemic shock or severe hypotension requiring intervention; significantly disabling (e.g., intraocular with permanent vision loss); associated with a decrease in Hb of at least 3 g/dL (or a fall in hematocrit (Hct) of at least 9%); transfusion of 2 or more units.PLATO Major bleed, fatal/life-threatening: any major bleed as described above and associated with a decrease in Hb of more than 5 g/dL (or a fall in hematocrit (Hct) of at least 15%); transfusion of 4 or more units.
Table 3 - Percentage of patients reporting non-hemorrhagic adverse reactions at least 4% or more in either group and more frequently on BRILINTA (PLATO)
BRILINTA90 mg BID N=9235Clopidogrel N=9186
Dyspnea13.87.8
Dizziness4.53.9
Nausea4.33.8
Table 4 - Bleeding events (PEGASUS)
BRILINTA60 mg BIDN=6958PlaceboN=6996
Events / 1000 patient yearsEvents / 1000 patient years
TIMI Major83
Fatal11
Intracranial hemorrhage21
TIMI Major or Minor115
TIMI Major: Fatal bleeding, OR any intracranial bleeding, OR clinically overt signs of hemorrhage associated with a drop in hemoglobin (Hgb) of ≥5 g/dL, or a fall in hematocrit (Hct) of ≥15%.Fatal: A bleeding event that directly led to death within 7 days.TIMI Minor: Clinically apparent with 3-5 g/dL decrease in hemoglobin.
Table 5 - Non-hemorrhagic adverse reactions reported in >3.0% of patients in the ticagrelor 60 mg treatment group (PEGASUS)
BRILINTA60 mg BID N=6958Placebo N=6996
Dyspnea14.2%5.5%
Dizziness4.5%4.1%
Diarrhea3.3%2.5%
Table 6 – Bleeding events (THEMIS)
BRILINTAN=9562PlaceboN=9531
Events / 1000 patient yearsEvents / 1000 patient years
TIMI Major94
TIMI Major or Minor125
TIMI Major or Minor or Requiring medical attention4618
Fatal bleeding10
Intracranial hemorrhage32

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Available data from case reports with BRILINTA use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Ticagrelor given to pregnant rats and pregnant rabbits during organogenesis caused structural abnormalities in the offspring at maternal doses about 5 to 7 times the maximum recommended human dose (MRHD) based on body surface area.

When ticagrelor was given to rats during late gestation and lactation, pup death and effects on pup growth were seen at approximately 10 times the MRHD (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data In reproductive toxicology studies, pregnant rats received ticagrelor during organogenesis at doses from 20 to 300 mg/kg/day. 20 mg/kg/day is approximately the same as the MRHD of 90 mg twice daily for a 60 kg human on a mg/m 2 basis.

Adverse outcomes in offspring occurred at doses of 300 mg/kg/day (16.5 times the MRHD on a mg/m 2 basis) and included supernumerary liver lobe and ribs, incomplete ossification of sternebrae, displaced articulation of pelvis, and misshapen/misaligned sternebrae. At the mid-dose of 100 mg/kg/day (5.5 times the MRHD on a mg/m 2 basis), delayed development of liver and skeleton was seen.

When pregnant rabbits received ticagrelor during organogenesis at doses from 21 to 63 mg/kg/day, fetuses exposed to the highest maternal dose of 63 mg/kg/day (6.8 times the MRHD on a mg/m 2 basis) had delayed gall bladder development and incomplete ossification of the hyoid, pubis and sternebrae occurred. In a prenatal/postnatal study, pregnant rats received ticagrelor at doses of 10 to 180 mg/kg/day during late gestation and lactation.

Pup death and effects on pup growth were observed at 180 mg/kg/day (approximately 10 times the MRHD on a mg/m 2 basis). Relatively minor effects such as delays in pinna unfolding and eye opening occurred at doses of 10 and 60 mg/kg (approximately one-half and 3.2 times the MRHD on a mg/m 2 basis).

Mechanism of action

12.1 Mechanism of Action Ticagrelor and its major metabolite reversibly interact with the platelet P2Y 12 ADP-receptor to prevent signal transduction and platelet activation. Ticagrelor and its active metabolite are approximately equipotent.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics The inhibition of platelet aggregation (IPA) by ticagrelor and clopidogrel was compared in a 6-week study examining both acute and chronic platelet inhibition effects in response to 20 μM ADP as the platelet aggregation agonist. The onset of IPA was evaluated on Day 1 of the study following loading doses of 180 mg ticagrelor or 600 mg clopidogrel.

As shown in Figure 5, IPA was higher in the ticagrelor group at all time points. The maximum IPA effect of ticagrelor was reached at around 2 hours, and was maintained for at least 8 hours. The offset of IPA was examined after 6 weeks on ticagrelor 90 mg twice daily or clopidogrel 75 mg daily, again in response to 20 μM ADP.

As shown in Figure 6, mean maximum IPA following the last dose of ticagrelor was 88% and 62% for clopidogrel. The insert in Figure 6 shows that after 24 hours, IPA in the ticagrelor group (58%) was similar to IPA in clopidogrel group (52%), indicating that patients who miss a dose of ticagrelor would still maintain IPA similar to the trough IPA of patients treated with clopidogrel.

After 5 days, IPA in the ticagrelor group was similar to IPA in the placebo group. It is not known how either bleeding risk or thrombotic risk track with IPA, for either ticagrelor or clopidogrel. Figure 5 - Mean inhibition of platelet aggregation (±SE) following single oral doses of placebo, 180 mg ticagrelor or 600 mg clopidogrel Figure 6 - Mean inhibition of platelet aggregation (IPA) following 6 weeks on placebo, ticagrelor 90 mg twice daily, or clopidogrel 75 mg daily Transitioning from clopidogrel to BRILINTA resulted in an absolute IPA increase of 26.4% and from BRILINTA to clopidogrel resulted in an absolute IPA decrease of 24.5%.

Patients can be transitioned from clopidogrel to BRILINTA without interruption of antiplatelet effect [see Dosage and Administration (2)]. figure_5 figure_6

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Excretion The primary route of ticagrelor elimination is hepatic metabolism.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Ticagrelor demonstrates dose proportional pharmacokinetics, which are similar in patients and healthy volunteers. Absorption BRILINTA can be taken with or without food. Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1.0–4.0). The formation of the major circulating metabolite AR-C124910XX (active) from ticagrelor occurs with a median t max of 2.5 h (range 1.5-5.0).

The mean absolute bioavailability of ticagrelor is about 36% (range 30%-42%). Ingestion of a high-fat meal had no effect on ticagrelor C max, but resulted in a 21% increase in AUC. The C max of its major metabolite was decreased by 22% with no change in AUC. BRILINTA as crushed tablets mixed in water, given orally or administered through a nasogastric tube into the stomach, is bioequivalent to whole tablets (AUC and C max within 80-125% for ticagrelor and AR-C124910XX) with a median t max of 1.0 hour (range 1.0 – 4.0) for ticagrelor and 2.0 hours (range 1.0 –8.0) for AR-C124910XX.

Distribution The steady state volume of distribution of ticagrelor is 88 L. Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%). Metabolism CYP3A4 is the major enzyme responsible for ticagrelor metabolism and the formation of its major active metabolite. Ticagrelor and its major active metabolite are weak P-glycoprotein substrates and inhibitors.

The systemic exposure to the active metabolite is approximately 30-40% of the exposure of ticagrelor. Ticagrelor is a BCRP inhibitor. Excretion The primary route of ticagrelor elimination is hepatic metabolism. When radiolabeled ticagrelor is administered, the mean recovery of radioactivity is approximately 84% (58% in feces, 26% in urine).

Recoveries of ticagrelor and the active metabolite in urine were both less than 1% of the dose. The primary route of elimination for the major metabolite of ticagrelor is most likely to be biliary secretion. The mean t 1/2 is approximately 7 hours for ticagrelor and 9 hours for the active metabolite. Specific Populations The effects of age, gender, ethnicity, renal impairment and mild hepatic impairment on the pharmacokinetics of ticagrelor are presented in Figure 7.

Effects are modest and do not require dose adjustment. Patients with End-Stage Renal Disease on Hemodialysis In patients with end stage renal disease on hemodialysis AUC and C max of BRILINTA 90 mg administered on a day without dialysis were 38% and 51% higher respectively, compared to subjects with normal renal function.

A similar increase in exposure was observed when BRILINTA was administered immediately prior to dialysis showing that BRILINTA is not dialyzable. Exposure of the active metabolite increased to a lesser extent. The IPA effect of BRILINTA was independent of dialysis in patients with end stage renal disease and similar to healthy adults with normal renal function.

Figure 7 - Impact of intrinsic factors on the pharmacokinetics of ticagrelor Effects of Other Drugs on BRILINTA CYP3A4 is the major enzyme responsible for ticagrelor metabolism and the formation of its major active metabolite. The effects of other drugs on the pharmacokinetics of ticagrelor are presented in Figure 8 as change relative to ticagrelor given alone (test/reference).

Strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, and clarithromycin) substantially increase ticagrelor exposure. Moderate CYP3A inhibitors have lesser effects (e.g., diltiazem). CYP3A inducers (e.g., rifampin) substantially reduce ticagrelor blood levels. P-gp inhibitors (e.g., cyclosporine) increase ticagrelor exposure.

Co-administration of 5 mg intravenous morphine with 180 mg loading dose of ticagrelor decreased observed mean ticagrelor exposure by up to 25% in healthy adults and up to 36% in ACS patients undergoing PCI. T max was delayed by 1-2 hours. Exposure of the active metabolite decreased to a similar extent. Morphine co-administration did not delay or decrease platelet inhibition in healthy adults.

Mean platelet aggregation was higher up to 3 hours post loading dose in ACS patients co-administered with morphine. Co-administration of intravenous fentanyl with 180 mg loading dose of ticagrelor in ACS patients undergoing PCI resulted in similar effects on ticagrelor exposure and platelet inhibition. Figure 8 - Effect of co-administered drugs on the pharmacokinetics of ticagrelor * See Dosage and Administration (2) Effects of BRILINTA on Other Drugs In vitro metabolism studies demonstrate that ticagrelor and its major active metabolite are weak inhibitors of CYP3A4, potential activators of CYP3A5 and inhibitors of the P-gp transporter.

In vitro metabolism studies demonstrate that ticagrelor is a BCRP inhibitor. Ticagrelor and AR-C124910XX were shown to have no inhibitory effect on human CYP1A2, CYP2C19, and CYP2E1 activity. For specific in vivo effects on the pharmacokinetics of simvastatin, atorvastatin, ethinyl estradiol, levonorgestrel, tolbutamide, digoxin and cyclosporine, see Figure 9.

Figure 9 - Impact of BRILINTA on the pharmacokinetics of co-administered drugs figure_7 figure_8 figure_9

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. BRILINTA · AstraZeneca Pharmaceuticals LP [US FDA-approved label, version 56, May 7, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b3f443-e83d-4bf2-0e96-023448fed9a8
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .